MX2015012741A - Palbociclib deuterado. - Google Patents

Palbociclib deuterado.

Info

Publication number: MX2015012741A
Authority: MX; Mexico
Prior art keywords: cdk; deuterated palbociclib; compositions; palbociclib; deuterated
Prior art date: 2013-03-15

Application number

MX2015012741A

Other languages

English (en)

Spanish (es)

Inventor

Adam J Morgan

Original Assignee

Concert Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-12

Publication date

2016-02-19

2014-03-12 Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc

2016-02-19 Publication of MX2015012741A publication Critical patent/MX2015012741A/es

Links

AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical class N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 title 1
239000000203 mixture Substances 0.000 abstract 2
MHHOMHMNIRXARC-UHFFFAOYSA-N 1h-pyrido[2,3-d]pyrimidin-2-one Chemical class C1=CN=C2NC(=O)N=CC2=C1 MHHOMHMNIRXARC-UHFFFAOYSA-N 0.000 abstract 1
101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MX2015012741A 2013-03-15 2014-03-12 Palbociclib deuterado. MX2015012741A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361787540P	2013-03-15	2013-03-15
PCT/US2014/024564 WO2014150925A2 (en)	2013-03-15	2014-03-12	Deuterated palbociclib

Publications (1)

Publication Number	Publication Date
MX2015012741A true MX2015012741A (es)	2016-02-19

Family

ID=51581623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2015012741A MX2015012741A (es)	2013-03-15	2014-03-12	Palbociclib deuterado.

Country Status (8)

Country	Link
US (3)	US20160024084A1 (2)
EP (2)	EP2970209B1 (2)
JP (1)	JP2016512831A (2)
AU (1)	AU2014235462C1 (2)
CA (1)	CA2904054A1 (2)
EA (2)	EA201892726A1 (2)
MX (1)	MX2015012741A (2)
WO (1)	WO2014150925A2 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20170032244A (ko)	2014-07-26	2017-03-22	선샤인 레이크 파르마 컴퍼니 리미티드	Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
CN105111201B (zh) *	2014-10-16	2017-01-11	上海页岩科技有限公司	5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2016092442A1 (en) *	2014-12-08	2016-06-16	Sun Pharmaceutical Industries Limited	Processes for the preparation of crystalline forms of palbociclib acetate
CN104892604B (zh) *	2015-06-19	2016-08-24	北京康立生医药技术开发有限公司	一种cdk4抑制剂的合成方法
CN105153149B (zh) *	2015-07-29	2017-09-19	江苏中邦制药有限公司	一种选择性激酶抑制剂Palbociclib的制备方法
US11225492B2 (en) *	2015-12-13	2022-01-18	Hangzhou Innogate Pharma Co., Ltd.	Heterocycles useful as anti-cancer agents
CN106967064B (zh) *	2017-03-29	2018-03-23	郑州泰基鸿诺医药股份有限公司	氘代Palbociclib的衍生物、制备方法及其应用
CN106986871B (zh) *	2017-03-29	2019-02-26	浙江同源康医药股份有限公司	一种氘代Palbociclib的晶型及其制备方法和应用
BR112021001499A2 (pt)	2018-07-27	2021-04-27	California Institute Of Technology	inibidores de cdk e usos dos mesmos
CN113166148B (zh) *	2018-12-07	2024-04-12	杭州英创医药科技有限公司	作为cdk-hdac双通路抑制剂的杂环化合物
WO2021113595A1 (en) *	2019-12-06	2021-06-10	Beta Pharma, Inc.	Phosphorus derivatives as kras inhibitors
LV15575A (lv)	2019-12-20	2021-06-20	Latvijas Organiskās Sintēzes Institūts	Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
TW354293B (en)	1995-06-06	1999-03-11	Bristol Myers Squibb Co	Prodrugs of paclitaxel derivatives
GB9925962D0 (en)	1999-11-02	1999-12-29	Novartis Ag	Organic compounds
HU229938B1 (en)	2001-05-03	2015-01-28	Hoffmann La Roche	Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en)	2001-05-24	2003-04-03	Alexza Pharmaceuticals, Inc.	Delivery of drug esters through an inhalation route
ES2251677T3 (es)	2002-01-22	2006-05-01	Warner-Lambert Company Llc	2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ATE412650T1 (de) *	2003-07-11	2008-11-15	Warner Lambert Co	Isethionat salz eines selektiven cdk4 inhibitors
US20060094744A1 (en)	2004-09-29	2006-05-04	Maryanoff Cynthia A	Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
TW200819441A (en)	2005-10-28	2008-05-01	Abbott Lab	Prodrugs of compounds that inhibit TRPV1 receptor
BRPI0716880A2 (pt) *	2006-09-08	2013-10-15	Pfizer Prod Inc	Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
CA2672898A1 (en)	2006-12-14	2008-06-26	Panacea Pharmaceuticals, Inc.	Methods of neuroprotection by cyclin-dependent kinase inhibition
US20090030005A1 (en)	2007-07-19	2009-01-29	Amgen Inc.	Combinations for the treatment of cancer
US9259399B2 (en)	2007-11-07	2016-02-16	Cornell University	Targeting CDK4 and CDK6 in cancer therapy
US7855204B2 (en) *	2008-01-22	2010-12-21	Concert Pharmaceuticals Inc.	Derivatives of gefitinib
JP2012504646A (ja)	2008-10-01	2012-02-23	ザユニバーシティオブノースカロライナアットチャペルヒル	選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh)	2008-10-01	2011-11-02	北卡罗来纳大学查珀尔希尔分校	使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
EP3406260B1 (en)	2009-05-13	2020-09-23	The University of North Carolina at Chapel Hill	Cyclin dependent kinase inhibitors and methods of use
UY33226A (es) *	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
WO2011130232A1 (en)	2010-04-13	2011-10-20	Novartis Ag	Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
CN101973989B (zh) *	2010-05-17	2012-07-18	苏州波锐生物医药科技有限公司	一种噻唑酰胺类化合物及其在治疗恶性肿瘤中的药物用途
EP2640394A4 (en)	2010-11-17	2015-02-25	Univ North Carolina	PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6

2014
- 2014-03-12 US US14/775,854 patent/US20160024084A1/en not_active Abandoned
- 2014-03-12 MX MX2015012741A patent/MX2015012741A/es unknown
- 2014-03-12 EA EA201892726A patent/EA201892726A1/ru unknown
- 2014-03-12 EA EA201591628A patent/EA032094B1/ru not_active IP Right Cessation
- 2014-03-12 CA CA2904054A patent/CA2904054A1/en not_active Abandoned
- 2014-03-12 AU AU2014235462A patent/AU2014235462C1/en not_active Ceased
- 2014-03-12 EP EP14769343.6A patent/EP2970209B1/en active Active
- 2014-03-12 JP JP2016501574A patent/JP2016512831A/ja active Pending
- 2014-03-12 EP EP18205631.7A patent/EP3492470A1/en not_active Withdrawn
- 2014-03-12 WO PCT/US2014/024564 patent/WO2014150925A2/en not_active Ceased
2017
- 2017-06-29 US US15/636,976 patent/US20180051022A1/en not_active Abandoned
2018
- 2018-11-13 US US16/189,304 patent/US20190225605A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20190225605A1 (en)	2019-07-25
WO2014150925A2 (en)	2014-09-25
EP3492470A1 (en)	2019-06-05
US20160024084A1 (en)	2016-01-28
CA2904054A1 (en)	2014-09-25
EP2970209B1 (en)	2018-12-26
EP2970209A2 (en)	2016-01-20
EP2970209A4 (en)	2016-08-31
EA201591628A1 (ru)	2016-03-31
AU2014235462A1 (en)	2015-09-17
US20180051022A1 (en)	2018-02-22
AU2014235462B2 (en)	2018-05-17
EA032094B1 (ru)	2019-04-30
AU2014235462C1 (en)	2018-11-01
EA201892726A1 (ru)	2019-04-30
WO2014150925A3 (en)	2014-12-04
JP2016512831A (ja)	2016-05-09

Publication	Publication Date	Title
MX2015012741A (es)	2016-02-19	Palbociclib deuterado.
MX2015008187A (es)	2016-02-05	Inhibidores de alk deuterados.
PH12018502125A1 (en)	2019-03-25	Bipyrazole derivatives as jak inhibitors
MX2016003823A (es)	2016-08-01	Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX365294B (es)	2019-05-29	Inhibidores de proteína cinasa dependiente de adn.
MD4800B1 (ro)	2022-03-31	Compuşi de aminopirimidinil ca inhibitori de JAK
MY196319A (en)	2023-03-24	Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
NZ700928A (en)	2017-06-30	Dna-pk inhibitors
IN2015DN01156A (2)	2015-06-26
MY178621A (en)	2020-10-19	Deuterated cftr potentiators
MX2018000396A (es)	2018-05-02	Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12016500953A1 (en)	2016-06-27	Tricyclic compounds as anticancer agents
PH12016500105A1 (en)	2016-04-18	Sulfonamides as modulators of sodium channels
MX389242B (es)	2025-03-20	Compuestos para su uso en el tratamiento de trastornos neuromusculares
WO2014028600A3 (en)	2014-04-24	3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
NZ726366A (en)	2018-05-25	Syk inhibitors
MX376164B (es)	2025-03-07	Composiciones y metodos para tratar el insomnio.
EA032271B9 (ru)	2019-08-30	Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MD20170011A2 (ro)	2017-08-31	Compuşi imidazopiridazinici
HK1254954A1 (zh)	2019-08-02	Lpt-723和免疫检查点抑制剂组合物及其治疗方法
MY191337A (en)	2022-06-16	Compositions for the treatment of hypertension and/or fibrosis
MX2018005004A (es)	2018-09-12	Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2017013099A (es)	2018-01-26	Metodos para el tratamiento de trastornos inflamatorios.
TN2015000524A1 (en)	2017-04-06	Pharmaceutical compositions
WO2013158698A3 (en)	2013-12-12	Method treating scleroderma